Two phase 3 trials will study Kura Oncology’s ziftomenib for frontline acute myeloid leukemia, one with venetoclax and the other with standard induction/consolidation.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/second-menin-inhibitor-approved-mutated-r-r-aml-2025a1000vl7?src=rss
Author :
Publish date : 2025-11-13 18:23:00
Copyright for syndicated content belongs to the linked Source.